Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News MMTEC Inc MTC

Technology Software - Application
Mmtec Inc is a China-based company primarily engaged in asset management services based on platforms. The Company is principally engaged in providing complete suite trading solutions, including fund creation, distribution, custody, trading and settlement services, to help these financial institutions accelerate their integration into overseas markets. The Company's systems include ETN counter... see more

Recent & Breaking News (NDAQ:MTC)

Results From Phase 2 CodeBreaK 100 Show LUMAKRAS(TM) (sotorasib) Is The First And Only KRAS G12C Inhibitor With Overall Survival Data

PR Newswire June 4, 2021

Midwest Eye Care Announces The Return of Mission Cataract

PR Newswire June 4, 2021

Novo Nordisk receives FDA approval for Wegovy(TM) to treat adults with obesity based on unprecedented efficacy for a prescription medicine in clinical trials

PR Newswire June 4, 2021

Liminal BioSciences Announces FDA Approval for its Biologics License Application for Ryplazim® (plasminogen, human-tvmh)

Canada NewsWire June 4, 2021

FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014

PR Newswire June 4, 2021

IEHP Welcomes Dr. Edward Juhn as New Chief Quality Officer

PR Newswire June 4, 2021

New Drug Effective Against Lung Cancers Caused by Common Genetic Error

PR Newswire June 4, 2021

Pennsylvania's Acting Physician General, Dr. Denise A. Johnson Named Chair of Patient Safety Authority Board

PR Newswire June 4, 2021

Cyteir Therapeutics Announces Presentation of First-in-Human Phase 1/2 Study of CYT-0851

PR Newswire June 4, 2021

Yale Cancer Center Study Shows Novel Test Can Detect New and Recurrent Bladder Cancer

PR Newswire June 4, 2021

Marathon Medical wins inclusion of the geko(TM) device on its Veterans Administration (VA) Federal Supply Schedule (FSS) contract

PR Newswire June 4, 2021

ADHD Medications Associated with Reduced Risk of Suicidality in Children with Significant Behavioral Symptoms

PR Newswire June 4, 2021

Recovery Unplugged Is Now In-Network with Humana

PR Newswire June 4, 2021

ASCO 2021: Cancer Patients Concerned About Vaccine Despite Few Adverse Effects

PR Newswire June 4, 2021

/R E P E A T -- Notice to the media - The Prime Minister, Ministers and Government of Canada officials to hold a news conference on coronavirus disease and COVID-19 vaccines in Canada/

Canada NewsWire June 4, 2021

MedWiz Pharmacy Announces the Opening of a New Long Term Care Pharmacy in Illinois

PR Newswire June 4, 2021

Hackensack University Medical Center and Hackensack Meridian School of Medicine Welcome Howard M. Ross, M.D. as Chair of Surgery/Surgeon-in-Chief

PR Newswire June 4, 2021

Alkermes Presents New Data on Nemvaleukin Alfa at 2021 American Society of Clinical Oncology Annual Meeting

PR Newswire June 4, 2021

Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy

PR Newswire June 4, 2021

Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC

PR Newswire June 4, 2021